Gut Microbiota in the Progression of Alpha-synucleinopathies

Launched by CHINESE UNIVERSITY OF HONG KONG · Apr 25, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how the bacteria in our gut might affect the progression of a condition called REM Sleep Behavior Disorder, which is often linked to early Parkinson's disease. Researchers want to see if the types of bacteria present in patients' guts at the beginning of the study can help predict how quickly their symptoms may worsen over time.

If you're considering participating, you should have previously completed a related study and not have taken probiotics or antibiotics in the last three months. Additionally, you should not have any serious gut diseases like inflammatory bowel disease, and you need to be able to understand and agree to take part in the study. Participants will have the chance to contribute to important research that could help improve the understanding of Parkinson's disease and its effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • recruit from the subjects who completed the baseline study
• Exclusion Criteria:
• • The use of probiotics or antibiotics within three months prior to sample collection;
• • Pre-existing gastrointestinal diseases, such as inflammatory bowel disease.
• • Not capable of giving informed consent for participation of the study.